TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2024

First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study.

Susanna Hegewisch-Becker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.